Comparing the current results to its competitors, Pds Biotechnology reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 37.09 %, recorded in the same quarter.
Pds Biotechnology's Comment on Competition and Industry Peers
The company considers its Versamune®, Versamune® combined with PDS01ADC, and Infectimune® platforms to offer competitive advantages. It faces competition from biotechnology and pharmaceutical companies, academic institutions, government agencies, and public and private research organizations. The company expects competition to intensify as new immunotherapies and advanced technologies emerge. Competitors may obtain FDA or other regulatory approvals more quickly, potentially securing strong market positions before the company enters. Key competitive factors include efficacy, safety, convenience, price, availability, generic competition, and reimbursement. Insurers and third-party payors may also impact competition by promoting the use of generic products.
September 9, 2024
: The realm of cancer immunotherapy continues to evolve, with innovative approaches aiming to enhance patient outcomes. PDS Biotech s recent announcement regarding the updated data presentation from their VERSATILE-002 trial at the upcoming ESMO Congress 2024 on September 14, 2024, highlights the ongoing quest for effective therapies against various malignancies. This article aims to synthesize the anticipated findings from this trial and their implications for cancer treatment.Immunotherapy has revolutionized the landscape of cancer treatment, providing new hope for patients with advanced malignancies. Among the burgeoning number of therapeutic strategies, personalized cancer vaccines and adjunct therapies...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Pds Biotechnology Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pds Biotechnology Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
